168 related articles for article (PubMed ID: 36369920)
1. Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection.
Perrotta F; Chino V; Allocca V; D'Agnano V; Bortolotto C; Bianco A; Corsico AG; Stella GM
Expert Rev Respir Med; 2022 Oct; 16(10):1043-1055. PubMed ID: 36369920
[TBL] [Abstract][Full Text] [Related]
2. [Can nivolumab be used safely in idiopathic pulmonary fibrosis?].
Duchemann B; Didier M; Pailler MC; Brillet PY; Kambouchner M; Uzunhan Y; Freynet O; Chouahnia K; Zelek L; Nunes H
Rev Mal Respir; 2019 Feb; 36(2):209-213. PubMed ID: 30686563
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer in patients with idiopathic pulmonary fibrosis.
Karampitsakos T; Tzilas V; Tringidou R; Steiropoulos P; Aidinis V; Papiris SA; Bouros D; Tzouvelekis A
Pulm Pharmacol Ther; 2017 Aug; 45():1-10. PubMed ID: 28377145
[TBL] [Abstract][Full Text] [Related]
4. Immune Stroma in Lung Cancer and Idiopathic Pulmonary Fibrosis: A Common Biologic Landscape?
Lettieri S; Oggionni T; Lancia A; Bortolotto C; Stella GM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809111
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive and practical approach to the management of idiopathic pulmonary fibrosis.
Moran-Mendoza O; Colman R; Kalluri M; Cabalteja C; Harle I
Expert Rev Respir Med; 2019 Jul; 13(7):601-614. PubMed ID: 31177864
[No Abstract] [Full Text] [Related]
6. Existing and emerging treatments for idiopathic pulmonary fibrosis.
Kolilekas L; Papiris S; Bouros D
Expert Rev Respir Med; 2019 Mar; 13(3):229-239. PubMed ID: 30632421
[TBL] [Abstract][Full Text] [Related]
7. [Radiotherapy of Lung Tumours in Idiopathic Pulmonary Fibrosis].
Kolek V; Vašáková M; Šterclová M; Cwiertka K; Vrána D; Kudláček A; Skřičková J; Pešek M; Petera J
Klin Onkol; 2017; 30(4):303-306. PubMed ID: 28832178
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and treatment standards in idiopathic pulmonary fibrosis in the era of antifibrotic drugs in Poland: A real-world practice survey.
Majewski S; Lewandowska K; Martusewicz-Boros MM; Piotrowski WJ
Adv Respir Med; 2019; 87(6):221-230. PubMed ID: 31970724
[TBL] [Abstract][Full Text] [Related]
9. Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies.
Biondini D; Balestro E; Sverzellati N; Cocconcelli E; Bernardinello N; Ryerson CJ; Spagnolo P
Expert Rev Respir Med; 2020 Apr; 14(4):405-414. PubMed ID: 31994940
[No Abstract] [Full Text] [Related]
10. Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis.
Naoi H; Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Inoue Y; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
Thorax; 2022 Jul; 77(7):727-730. PubMed ID: 35354649
[TBL] [Abstract][Full Text] [Related]
11. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.
Aryal S; Nathan SD
Expert Opin Emerg Drugs; 2018 Jun; 23(2):159-172. PubMed ID: 29718783
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
Yamamoto Y; Yano Y; Kuge T; Okabe F; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
Thorac Cancer; 2020 Nov; 11(11):3317-3325. PubMed ID: 32986306
[TBL] [Abstract][Full Text] [Related]
13. Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review.
Antoniou K; Kamekis A; Symvoulakis EK; Kokosi M; Swigris JJ
Curr Opin Pulm Med; 2020 Sep; 26(5):457-463. PubMed ID: 32701673
[TBL] [Abstract][Full Text] [Related]
14. [Research Progress on Pathogenic Mechanism and Potential Therapeutic Drugs of
Idiopathic Pulmonary Fibrosis Complicated with Non-small Cell Lung Cancer].
Xiao T; Bao J; Liu X; Huang H; Zhou H
Zhongguo Fei Ai Za Zhi; 2022 Oct; 25(10):756-763. PubMed ID: 36167462
[TBL] [Abstract][Full Text] [Related]
15. Idiopathic Pulmonary Fibrosis Among Young Patients: Challenges in Diagnosis and Management.
Leuschner G; Reiter F; Stocker F; Crispin A; Kneidinger N; Veit T; Klenner F; Ceelen F; Zimmermann G; Leuchte H; Reu S; Dinkel J; Behr J; Neurohr C
Lung; 2018 Aug; 196(4):401-408. PubMed ID: 29761229
[TBL] [Abstract][Full Text] [Related]
16. Severe idiopathic pulmonary fibrosis: A clinical approach.
Lipsi R; Mazzola D; Caminati A; Elia D; Lonati C; Harari S
Eur J Intern Med; 2018 Apr; 50():20-27. PubMed ID: 29361476
[TBL] [Abstract][Full Text] [Related]
17. A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer.
Vancheri C; du Bois RM
Eur Respir J; 2013 Feb; 41(2):262-9. PubMed ID: 22903965
[TBL] [Abstract][Full Text] [Related]
18. Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer.
Tzouvelekis A; Gomatou G; Bouros E; Trigidou R; Tzilas V; Bouros D
Chest; 2019 Aug; 156(2):383-391. PubMed ID: 31125557
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic pulmonary fibrosis (IPF) - common practice in Poland before the "antifibrotic drugs era".
Piotrowski WJ; Martusewicz-Boros MM; Białas AJ; Lewandowska K
Adv Respir Med; 2017; 85(3):136-142. PubMed ID: 28667654
[TBL] [Abstract][Full Text] [Related]
20. New therapeutics based on emerging concepts in pulmonary fibrosis.
Sontake V; Gajjala PR; Kasam RK; Madala SK
Expert Opin Ther Targets; 2019 Jan; 23(1):69-81. PubMed ID: 30468628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
